Genetic variations associated with cisplatin-induced ototoxicity identified
the ONA take:
The anti-cancer drug cisplatin is widely administered to treat brain cancer and other tumors, but some individuals treated with cisplatin experience severe hearing loss, among other side effects.
But the effect of patients varies widely. The reasons why some patients were affected has not been fully understood, but a group of investigators based at St. Jude Children's Research Hospital feel the cause of rooted in genetic variations.
The research team examined DNA from 238 patients with brain tumors and took into account some 1.7 million common genetic variations, looking for a link to the cisplatin-related hearing loss. This was the first time a possible genetic cause of this side effect had been investigated.
The result: genetic variations in a gene called ACYP2 were linked to as much as a four-fold increase of risk for hearing loss. This association was verified in a separate group of 68 patients after other risk factors, such as radiation treatment or age, were eliminated. Individuals with at least one copy of the ACYP2 variant experienced hearing loss, establishing a link to that genetic variation, but additional individuals also experienced hearing loss so the researchers feel other, not-yet-identified genetic variations are also at play.
This research could be the first step in identified patients receiving cisplatin that are at high risk of hearing loss. Additional research into why the ACYP2 variations actually trigger the hearing is needed.
The anti-cancer drug cisplatin is widely administered to treat brain cancer and other tumors.
Sign Up for Free e-newsletters
- Hodgkin Lymphoma Survivorship Marked by Periods of Actionable Distress
- Medication, Vaccination Uptake Improved by Involving Pharmacists in Elder Cancer Care
- Molecular Features May Predict Response in Primary Pancreatic Cancer
- Stem Cell Transplantation Superior to Chemotherapy for Relapsed/Refractory DLBCL, Follicular Lymphoma
- Commission Seeks Standardized Adverse Event Assessments in Hematologic Malignancies
- Navigating Prostate Cancer: A Patient's Experience From Diagnosis to Survivor
- Cell Phones and Cancer Risk (Fact Sheet)
- How Likely Are Oncologists to Refer for Palliative Care? Depends on Their Age
- Use of Corticosteroids With PD-1 or PD-L1 Inhibitors Associated With Poorer Outcomes in NSCLC
- Chemoimmunotherapy Increases Survival in Triple-Negative Breast Cancer
- Integrative Medicine in Childhood Cancer: Practices That Can Help Pediatric Patients
- Clinical Characteristics That Increase Risk of Chemotherapy-Induced Febrile Neutropenia Identified
- Dose-Escalation Mitigates Risk of Grade 3/4 Adverse Events With Ruxolitinib for Myelofibrosis
- Counseling Patients on Oral Chemotherapy
- Patients and Caregivers Worry About Cost of Cancer Care
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|